{"entity":{"id":"nct07186842","kind":"trial","name":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","aka":[],"tldr":"A phase 1/2 trial of BNT329 in advanced solid tumours, run by BioNTech SE, now recruiting.","summary":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 is a phase 1/2 interventional study registered as NCT07186842 by BioNTech SE, with 245 participants planned, started 2025-11-18 and due to reach its primary completion in 2030-05. Interventions recorded: BNT329 and CA19-9-targeting monoclonal antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07186842","url":"https://clinicaltrials.gov/study/NCT07186842"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07186842","phase":"1/2","setting":"First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9","sponsor":"BioNTech SE","enrolled":245,"outcomes":[]},"route":"/trials/nct07186842/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"}]}}